Belimumab in SLE with Mucocutaneous or Vasculitis Findings Save

A post hoc analysis of a belimumab (BEL) inn systemic lupus erythematosus (SLE) study showed lupus mucocutaneous and vasculitic  manifestations improve with BEL and standard care.

 

A post hoc study included pooled data from belimumab trials (Be-SLE; BLISS-52, BLISS-76, BLISS-SC, and EMBRACE) conducted between 2007 and 2018. Adults with active SLE were treated with either BEL (10 mg/kg/month intravenously or 200 mg/week subcutaneously) or placebo, plus standard therapy (ST). Lupus outcomes were assessed using SELENA-SLEDAI and British Isles Lupus Assessment Group (BILAG).

 

Of 3086 patients, 85% (by SELENA-SLEDAI) and 58-62% (by BILAG) had mucocutaneous manifestations, and <10% had vasculitis at baseline. At Week 52, BEL-treated MC/V patients had significantly better outcomes compared to PBO: 

Significant differences between-treatment favored BEL SELENA-SLEDAI MC/V domains (vasculitis, rash, alopecia, and mucosal ulcers), and 9/20 BILAG domains (mild maculopapular eruption, localized active discoid lesions, mild alopecia, small mucosal ulceration, malar erythema, subcutaneous nodules, swollen fingers, major cutaneous vasculitis including ulcers, and minor cutaneous vasculitis).

 

BEL has demonstrated clinical improvements in mucocutaneous and vasculitis manifestations.